Ophthotech Changes Name to Iveric bio


NEW YORK—Ophthotech Corp. (Nasdaq:OPHT) announced yesterday that it is changing its name to Iveric bio, Inc. The company said the new name reflects its transition strategy “to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs.” In conjunction with the corporate name change, the company will trade on the Nasdaq Global Select Market under the new ticker symbol “ISEE.” The new ticker symbol become effective yesterday. Iveric bio has launched a new corporate website, www.ivericbio.com.

“We are excited about our rebranding and corporate name change reflecting our transition to a gene therapy focused company developing treatments for patients with orphan inherited retinal diseases,” said Glenn P. Sblendorio, CEO and president of Iveric bio. “We are executing a strategy that leverages our retinal expertise and provides a clear path forward with multiple orphan IRD gene therapy programs. We believe this is an important time for the Company as we advance our diversified pipeline of scientifically compelling gene therapy programs and explore new gene therapy opportunities for the treatment of orphan IRDs and generate value for our shareholders.”